MX335951B - Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades. - Google Patents

Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.

Info

Publication number
MX335951B
MX335951B MX2012002681A MX2012002681A MX335951B MX 335951 B MX335951 B MX 335951B MX 2012002681 A MX2012002681 A MX 2012002681A MX 2012002681 A MX2012002681 A MX 2012002681A MX 335951 B MX335951 B MX 335951B
Authority
MX
Mexico
Prior art keywords
pth
week
units
unit dose
administered once
Prior art date
Application number
MX2012002681A
Other languages
English (en)
Other versions
MX2012002681A (es
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Yuiko Oya
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX335951(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of MX2012002681A publication Critical patent/MX2012002681A/es
Publication of MX335951B publication Critical patent/MX335951B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen: un método para el tratamiento de la osteoporosis usando PTH que es altamente seguro y tiene alto efecto/eficacia; un método para inhibir/prevenir fracturas óseas usando PTH que es altamente seguro; y un agente medicinal para usarse en cada uno de los métodos anteriores. Específicamente, se describe un agente medicinal que comprende PTH como un ingrediente activo, el cual se caracteriza porque la PTH se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades en cada uno de los métodos mencionados anteriormente.
MX2012002681A 2009-09-09 2010-09-08 Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades. MX335951B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (ja) 2009-09-09 2010-09-08 １回当たり１００～２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤

Publications (2)

Publication Number Publication Date
MX2012002681A MX2012002681A (es) 2012-04-19
MX335951B true MX335951B (es) 2016-01-04

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002681A MX335951B (es) 2009-09-09 2010-09-08 Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.

Country Status (17)

Country Link
US (3) US20120252729A1 (es)
EP (3) EP2682125B1 (es)
JP (13) JPWO2011030774A1 (es)
KR (8) KR102424644B1 (es)
CN (2) CN102470164B (es)
AU (1) AU2010293488B2 (es)
BR (1) BR112012003511A2 (es)
CA (1) CA2772656A1 (es)
ES (3) ES2662018T3 (es)
HK (1) HK1168284A1 (es)
IL (1) IL217854A (es)
IN (1) IN2012DN00857A (es)
MX (1) MX335951B (es)
NZ (2) NZ617397A (es)
RU (1) RU2564894C2 (es)
WO (1) WO2011030774A1 (es)
ZA (1) ZA201201720B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102686236A (zh) * 2009-11-18 2012-09-19 旭化成制药株式会社 人变形性膝关节症的预防剂和/或治疗剂和/或恶化抑制剂
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
CN111032073A (zh) * 2017-09-22 2020-04-17 旭化成制药株式会社 药物动力学和/或安全性优异的含有特立帕肽的液态药物组合物
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
JP7080487B2 (ja) 2018-09-26 2022-06-06 東陽建設工機株式会社 鉄筋曲げ方法
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI293563B (en) 2000-06-30 2008-02-21 Asubio Pharma Co Ltd Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) * 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
US20070155664A1 (en) * 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JPWO2005102381A1 (ja) * 2004-04-26 2008-03-06 小野薬品工業株式会社 カテプシンｋ阻害薬およびｐｔｈ類を併用することを特徴とする骨密度増加剤
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
EP2311505B1 (en) * 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
EP2001453A4 (en) * 2006-03-15 2012-09-12 Alza Corp APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS FOR TREATING OR PREVENTING OSTEOPENIA
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
JP2017105861A (ja) 2017-06-15
JP2016130261A (ja) 2016-07-21
JP6198346B2 (ja) 2017-09-20
RU2564894C2 (ru) 2015-10-10
ES2843649T3 (es) 2021-07-20
ES2663322T3 (es) 2018-04-12
EP2476429B1 (en) 2018-03-07
EP2682124B1 (en) 2018-02-28
EP2682125A1 (en) 2014-01-08
WO2011030774A1 (ja) 2011-03-17
KR20150021590A (ko) 2015-03-02
AU2010293488A1 (en) 2012-03-29
JP2017105858A (ja) 2017-06-15
US20140249084A1 (en) 2014-09-04
JP6043008B2 (ja) 2016-12-14
IL217854A (en) 2016-08-31
EP2682124A1 (en) 2014-01-08
IL217854A0 (en) 2012-03-29
JP6522715B2 (ja) 2019-05-29
KR102424644B1 (ko) 2022-07-25
CN102470164B (zh) 2014-04-09
KR20140130754A (ko) 2014-11-11
JPWO2011030774A1 (ja) 2013-02-07
ES2662018T3 (es) 2018-04-05
KR20170089018A (ko) 2017-08-02
EP2476429A1 (en) 2012-07-18
HK1168284A1 (en) 2012-12-28
EP2476429A4 (en) 2013-02-27
JP6150846B2 (ja) 2017-06-21
JP2017105862A (ja) 2017-06-15
JP2017105863A (ja) 2017-06-15
KR20200115673A (ko) 2020-10-07
CN103893746A (zh) 2014-07-02
JP2017105859A (ja) 2017-06-15
KR102335703B1 (ko) 2021-12-07
BR112012003511A2 (pt) 2019-09-24
MX2012002681A (es) 2012-04-19
AU2010293488B2 (en) 2014-11-27
JP2015147813A (ja) 2015-08-20
CA2772656A1 (en) 2011-03-17
NZ617397A (en) 2015-02-27
RU2012108635A (ru) 2013-10-20
KR20170089017A (ko) 2017-08-02
KR20210040171A (ko) 2021-04-12
US20120252729A1 (en) 2012-10-04
JP2019023234A (ja) 2019-02-14
IN2012DN00857A (es) 2015-07-10
US20140357560A1 (en) 2014-12-04
JP2017061511A (ja) 2017-03-30
JP6275900B2 (ja) 2018-02-07
KR20120067336A (ko) 2012-06-25
NZ598370A (en) 2014-04-30
CN102470164A (zh) 2012-05-23
JP6301524B2 (ja) 2018-03-28
KR20190095552A (ko) 2019-08-14
JP2017105860A (ja) 2017-06-15
ZA201201720B (en) 2012-11-28
JP2015157854A (ja) 2015-09-03
JP2018024710A (ja) 2018-02-15
EP2682125B1 (en) 2020-11-04
JP6274634B2 (ja) 2018-02-07

Similar Documents

Publication Publication Date Title
MX2012002681A (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
MY168791A (en) Carbamate compounds and of making and using same
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
MX344329B (es) Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
WO2011044523A3 (en) Compositions and methods for treating obesity
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
EP2575456A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECCHYMOSIS
IL250852B (en) Periodontal preparation
MX339484B (es) Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.
NZ613264A (en) Use of vitamin k for weight maintenance and weight control
UA97044C2 (ru) Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней
EA201892706A1 (ru) Комбинированная терапия для лечения рассеянного склероза
IN2013MU01154A (es)
UA64165U (ru) Способ лечения пациентов с травмами мягких тканей конечностей
IN2013MU01155A (es)
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis